Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective

References

• Graham D, Adam E, Reddy G et al. Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig. Dis. Sci.36(8), 1084–1088 (1991).
   PubMed Web of Science ®Google Scholar
• Graham D, Malaty H, Evans D, Evans DJ, Klein P, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology100(6), 1495–1501 (1991).
   PubMed Web of Science ®Google Scholar
• Karita M, Teramukai S, Matsumoto S. Risk of Helicobacter pylori transmission from drinking well water is higher than that from infected intrafamilial members in Japan. Dig. Dis. Sci.48(6), 1062–1067 (2003).
   PubMedGoogle Scholar
• Asaka M, Kimura T, Kudo M et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology102(3), 760–766 (1992).
   PubMed Web of Science ®Google Scholar
• Graham D, Reddy S. Rapid detection of anti-Helicobacter pylori IgG in urine using immunochromatography. Aliment. Pharmacol. Ther.15(5), 699–702 (2001).
   PubMedGoogle Scholar
• Kumagai T, Malaty H, Graham D et al. Acquisition versus loss of Helicobacter pylori infection in Japan: results from an 8-year birth cohort study. J. Infect. Dis.178(3), 717–721 (1998).
   PubMed Web of Science ®Google Scholar
• Japanese Society for Helicobacter Research Committee on Guidelines. Guidelines for the management of Helicobacter pylori infection in Japan. J. Jpn Soc. Helicobacter Res.1(Suppl. 1), 1–12 (2000).
   Google Scholar
• Asaka M, Satoh K, Sugano K et al. Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter6(3), 177–186 (2001).
   PubMed Web of Science ®Google Scholar
• Japanese Society for Helicobacter Research Committee on Guidelines. Guidelines for the management of Helicobacter pylori infection in Japan. Revised edition. J. Jpn Soc. Helicobacter Res.4(Suppl. 1), 1–15 (2003).
   Google Scholar
• Fujioka T, Yoshiiwa A, Okimoto T, Kodama M, Murakami K. Guidelines for the management of Helicobacter pylori infection in Japan: current status and future prospects. J. Gastroenterol.42(Suppl. 17), 3–6 (2003).
   Google Scholar
• Japanese Society for Helicobacter Research Committee on Guidelines. Guidelines for the management of Helicobacter pylori infection in Japan. Revised edition. J. Jpn Soc. Helicobacter Res.10(Suppl. 1), 1–25 (2009).
   Google Scholar
• Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet372(9636), 392–397 (2008).
   PubMed Web of Science ®Google Scholar
• NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA272(1), 65–69 (1994).
   PubMed Web of Science ®Google Scholar
• Uemura N, Okamoto S, Yamamoto S et al.Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med.345(11), 784–789 (2001).
   PubMed Web of Science ®Google Scholar
• Wotherspoon A, Ortiz-Hidalgo C, Falzon M, Isaacson P. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet338(8776), 1175–1176 (1991).
   PubMed Web of Science ®Google Scholar
• D’Elios M, Appelmelk B, Amedei A, Bergman M, Del Prete G. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol. Med.10(7), 316–323 (2004).
   PubMed Web of Science ®Google Scholar
• Gisbert J, Khorrami S, Carballo F, Calvet X, Gené E, Dominguez-Muñoz J. H. pylori eradication therapy vs antisecretory noneradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst. Rev.CD004062 (2004).
   Google Scholar
• Miwa H, Sakaki N, Sugano K et al. Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter9(1), 9–16 (2004).
   PubMedGoogle Scholar
• Lai K, Lau C, Ip W et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment. Pharmacol. Ther.17(6), 799–805 (2003).
   PubMed Web of Science ®Google Scholar
• Vergara M, Catalán M, Gisbert J, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment. Pharmacol. Ther.21(12), 1411–1418 (2005).
   PubMed Web of Science ®Google Scholar
• Lai K, Lam S, Chu K et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med.346(26), 2033–2038 (2002).
   PubMed Web of Science ®Google Scholar
• Lai K, Lam S, Chu K et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users – a randomized trial. Aliment. Pharmacol. Ther.18(8), 829–836 (2003).
   PubMed Web of Science ®Google Scholar
• Stolte M, Eidt S. Healing gastric MALT lymphomas by eradicating H. pylori? Lancet342(8871), 568 (1993).
   PubMedGoogle Scholar
• Wotherspoon A, Doglioni C, Diss T et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet342(8871), 575–577 (1993).
   PubMed Web of Science ®Google Scholar
• Bayerdörffer E, Neubauer A, Rudolph B et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet345(8965), 1591–1594 (1995).
   PubMed Web of Science ®Google Scholar
• Inagaki H, Nakamura T, Li C et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter pylori eradication and detection of API2-MALT1 fusion. Am. J. Surg. Pathol.28(12), 1560–1567 (2004).
   PubMed Web of Science ®Google Scholar
• Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet352(9131), 878 (1998).
   PubMed Web of Science ®Google Scholar
• Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J. Antimicrob. Chemother.60(2), 237–246 (2007).
   PubMed Web of Science ®Google Scholar
• Ando K, Shimamoto T, Tauchi T et al. Can eradication therapy for Helicobacter pylori really improve the thrombocytopenia in idiopathic thrombocytopenic purpura? Our experience and a literature review. Int. J. Hematol.77(3), 239–244 (2003).
   PubMed Web of Science ®Google Scholar
• Fujimura K, Kuwana M, Kurata Y et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int. J. Hematol.81(2), 162–168 (2005).
   PubMed Web of Science ®Google Scholar
• Sato R, Murakami K, Watanabe K et al. Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch. Intern. Med.164(17), 1904–1907 (2004).
   PubMedGoogle Scholar
• Everhart J, Kruszon-Moran D, Perez-Perez G, Tralka T, McQuillan G. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J. Infect. Dis.181(4), 1359–1363 (2000).
   PubMed Web of Science ®Google Scholar
• Michel M, Khellaf M, Desforges L et al. Autoimmune thrombocytopenic Purpura and Helicobacter pylori infection. Arch. Intern. Med.162(9), 1033–1036 (2002).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Yujiri T, Tanizawa Y. Helicobacter pylori and chronic ITP: the discrepancy in the clinical responses to eradication therapy might be due to differences in the bacterial strains. Blood104(2), 594 (2004).
   PubMed Web of Science ®Google Scholar
• Byrne M, Kerrigan S, Corcoran P et al.Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology124(7), 1846–1854 (2003).
   PubMed Web of Science ®Google Scholar
• Veneri D, De Matteis G, Solero P et al. Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: correlation with Helicobacter pylori infection and response to eradication treatment. Platelets16(5), 307–311 (2005).
   PubMed Web of Science ®Google Scholar
• Uemura N, Mukai T, Okamoto S et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol. Biomarkers Prev.6(8), 639–642 (1997).
   PubMed Web of Science ®Google Scholar
• Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter12(Suppl. 2), 32–38 (2007).
   PubMed Web of Science ®Google Scholar
• Ohkusa T, Takashimizu I, Fujiki K et al. Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. Ann. Intern. Med.129(9), 712–715 (1998).
   PubMedGoogle Scholar
• Ji F, Wang Z, Ning J, Wang Q, Chen J, Li Y. Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. World J. Gastroenterol.12(11), 1770–1773 (2006).
   PubMedGoogle Scholar
• Malfertheiner P, Megraud F, O’Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut56(6), 772–781 (2007).
   PubMed Web of Science ®Google Scholar
• Miwa H, Hirai S, Nagahara A et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Aliment. Pharmacol. Ther.14(3), 317–324 (2000).
   PubMed Web of Science ®Google Scholar
• Kamada T, Haruma K, Hata J et al. The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment. Pharmacol. Ther.18(2), 245–252 (2003).
   PubMed Web of Science ®Google Scholar
• Azuma T, Ito Y, Suto H et al. The effect of Helicobacter pylori eradication therapy on dyspepsia symptoms in industrial workers in Japan. Aliment. Pharmacol. Ther.15(6), 805–811 (2001).
   PubMedGoogle Scholar
• Suzuki H, Masaoka T, Sakai G, Ishii H, Hibi T. Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy. J. Gastroenterol. Hepatol.20(11), 1652–1660 (2005).
   PubMedGoogle Scholar
• Shiota S, Murakami K, Takayama A et al. Evaluation of Helicobacter pylori status and endoscopic findings among new outpatients with dyspepsia in Japan. J. Gastroenterol.44(9), 930–934 (2009).
   PubMedGoogle Scholar
• Kawanishi M. Development of reflux esophagitis following Helicobacter pylori eradication. J. Gastroenterol.40(11), 1024–1028 (2005).
   PubMed Web of Science ®Google Scholar
• Sasaki A, Haruma K, Manabe N, Tanaka S, Yoshihara M, Chayama K. Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. Aliment. Pharmacol. Ther.17(12), 1529–1534 (2003).
   PubMedGoogle Scholar
• Tsukada K, Miyazaki T, Katoh H et al. The incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori. Eur. J. Gastroenterol. Hepatol.17(10), 1025–1028 (2005).
   PubMedGoogle Scholar
• Chey W. Proton pump inhibitors and the urea breath test: how long is long enough? Am. J. Gastroenterol.92(4), 720–721 (1997).
   PubMedGoogle Scholar
• Laine L, Estrada R, Trujillo M, Knigge K, Fennerty M. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann. Intern. Med.129(7), 547–550 (1998).
   PubMed Web of Science ®Google Scholar
• Graham D, Opekun A, Hammoud F et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am. J. Gastroenterol.98(5), 1005–1009 (2003).
   PubMed Web of Science ®Google Scholar
• Kuwayama H, Asaka M, Sugiyama T et al. Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. Aliment. Pharmacol. Ther.25(9), 1105–1113 (2007).
   PubMed Web of Science ®Google Scholar
• Murakami K, Sato R, Okimoto T et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment. Pharmacol. Ther.17(1), 119–123 (2003).
   PubMed Web of Science ®Google Scholar
• Shimoyama T, Fukuda S, Mikami T, Fukushi M, Munakata A. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population. J. Gastroenterol.39(10), 927–930 (2004).
   PubMed Web of Science ®Google Scholar
• Fukuda S, Shimoyama T, Tanaka M, Nakasato F, Fukushi M, Munakata A. Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in northern Japan. Jpn J. Infect. Dis.59(6), 367–369 (2006).
   PubMed Web of Science ®Google Scholar
• Murakami K, Okimoto T, Kodama M, Sato R, Watanabe K, Fujioka T. Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. J. Clin. Gastroenterol.42(2), 139–142 (2008).
   PubMed Web of Science ®Google Scholar
• Kobayashi I, Murakami K, Kato M et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J. Clin. Microbiol.45(12), 4006–4010 (2007).
   PubMed Web of Science ®Google Scholar